Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Stockholders Equity Over TimeContracting
Percentile Rank14
3Y CAGR-41.4%
5Y CAGR-32.3%
Studio
Year-over-Year Change

Net worth of the company (assets minus liabilities)

3Y CAGR
-41.4%/yr
vs -4.9%/yr prior
5Y CAGR
-32.3%/yr
Recent deceleration
Acceleration
-36.4pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
6 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$64.72M-49.8%
2024$128.81M-40.6%
2023$216.74M-32.6%
2022$321.33M-19.6%
2021$399.43M-12.3%
2020$455.58M-1.5%
2019$462.49M+17.5%
2018$393.68M+30.5%
2017$301.68M+11.8%
2016$269.94M-